Update on eltrombopag for ITP

ONCOLOGY

Volumn 23, Issue 13, 2009, Pages

  Bussel, James B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ELTROMBOPAG; IMMUNOGLOBULIN; PLACEBO; PROMACTA INFLUENZA H1N1; ROMIPLOSTIM; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER TOXICITY; PROTEIN DEPOSITION; RETICULIN DEPOSITION; REVIEW; SIDE EFFECT; SPLENECTOMY; THROMBOEMBOLISM;

EID: 73349086852     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Bussel JB, Provan D, Shamsi T, et al: Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet 373:641-648, 2009.
2. Bussel JB, Cheng G, Saleh MN, et al: Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357:2237-2247, 2007.
3. Cheng G, Saleh MN, Bussel JB, et al: Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: Results of a phase III, double-blind, placebo-controlled study (RAISE) (abstract 400). Blood 112(11), 2008.
4. Kuter DJ, Bussel JB, Lyons RM, et al: Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomized controlled trial. Lancet 371:395-403, 2008.
5. Bussel JB, Kuter DJ, Pullarkat V, et al: Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113:2161-2171, 2009.
6. Saleh MN, Bussel JB, Cheng G, et al: Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: Results from the EXTEND study. American Society of Hematology meeting, New Orleans, 2009.
7. McHutchison JG, Dusheiko G, Shiffman ML, et al: Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357:2227-2236, 2007.
8. Maddrey W, Cheng G, Khelif A, et al: Evaluation of hepatobiliary parameters during eltrombopag treatment in patients with chronic immune thrombocytopenic purpura. American Society of Hematology meeting, New Orleans, 2009.
9. Cheng G, Tarantino MD, Gernsheimer T, et al: Platelet counts following eltrombopag discontinuation in patients with chronic immune thrombocytopenic purpura. American Society of Hematology meeting, New Orleans, 2009.
10. Bussel JB, Cheng G, Saleh MN, et al: Thromboembolic events observed in eltrombopag clinical trials in chronic immune thrombocytopenic purpura. American Society of Hematology meeting, New Orleans, 2009.
11. Aledort LM, Hayward C, Chen MG, et al: Prospective screening of 205 patients with ITP including diagnosis, serological markers, and the relationship of platelet counts, endogenous thrombopoietin, and circulating anti-thrombopoietin antibodies. Am J Hematol 76:205-213, 2004.
12. Kile BT: The role of the intrinsic apoptosis pathway in platelet life and death. J Thromb Haemost 7(suppl 1):214-217, 2009.
13. Buchanan GR, Bomgaars L, Bussel JB, et al: A randomized, double-blind, placebo-controlled phase 1/2 study to determine the safety and efficacy of romiplostim in children with chronic immune (idiopathic) thrombocytopenic purpura (ITP). American Society of Hematology meeting, New Orleans, 2009.